PHAT Stock Price, Phathom Pharmaceuticals Quote, Chart

Market Summary

USD10.36+0.69

Market Closed

7.14%

PHAT Stock Price

View Fullscreen

PHAT RSI Chart

PHAT Valuation

Market Cap

566.0M

Price/Earnings (Trailing)

-2.3

Price/Sales (Trailing)

829.96

Price/Free Cashflow

-3.36

PHAT Price/Sales (Trailing)

PHAT Profitability

Operating Margin

75.51%

Return on Equity

166.08%

Return on Assets

-69.18%

Free Cashflow Yield

-29.75%

PHAT Fundamentals

PHAT Revenue

Revenue (TTM)

682.0K

PHAT Earnings

Earnings (TTM)

-246.6M

Earnings Growth (Yr)

-119.1%

Earnings Growth (Qtr)

-4.12%

Breaking Down PHAT Revenue

Last 7 days

-10.8%

Last 30 days

-4.6%

Last 90 days

55.7%

Trailing 12 Months

-28.2%

How does PHAT drawdown profile look like?

PHAT Financial Health

Current Ratio

7.83

Debt/Equity

-1

Debt/Cashflow

-1.12

PHAT Investor Care

Shares Dilution (1Y)

34.21%

Diluted EPS (TTM)

-4.47

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	0	0	0	682.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Phathom Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 08, 2024	henderson molly	sold	-38,128	11.1	-3,435	cfo and cbo
Mar 22, 2024	curran terrie	sold	-153,513	9.11	-16,851	president and chief executive
Jan 24, 2024	takeda pharmaceutical co ltd	sold	-30,000,000	8.1	-3,703,700	-
Jan 19, 2024	henderson molly	sold	-48,900	7.7533	-6,307	cfo and cbo
Nov 20, 2023	henderson molly	sold	-15,402	7.2415	-2,127	cfo and cbo
Nov 08, 2023	parikh asit	bought	19,500	7.8	2,500	-
Nov 07, 2023	parikh asit	bought	31,040	7.76	4,000	-
Nov 06, 2023	parikh asit	bought	8,040	8.04	1,000	-
Nov 01, 2023	henderson molly	acquired	-	-	22,500	cfo and cbo
Nov 01, 2023	nabulsi azmi	acquired	-	-	32,500	chief operating officer

Which funds bought or sold PHAT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	VANGUARD GROUP INC	added	1.16	3,155,980	21,018,200	-%
May 10, 2024	BlackRock Inc.	added	2.48	4,697,660	29,155,900	-%
May 10, 2024	GROUP ONE TRADING, L.P.	sold off	-100	-14,106	-	-%
May 10, 2024	JPMORGAN CHASE & CO	reduced	-5.19	137,043	1,470,360	-%
May 10, 2024	CITIGROUP INC	added	7.01	12,623	64,198	-%
May 10, 2024	OSAIC HOLDINGS, INC.	reduced	-17.56	-103	2,442	-%
May 10, 2024	PNC Financial Services Group, Inc.	added	22.96	530	1,763	-%
May 10, 2024	CREDIT SUISSE AG/	added	4.33	74,165	421,434	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	added	6.57	23,819	123,245	-%
May 09, 2024	LANDSCAPE CAPITAL MANAGEMENT, L.L.C.	sold off	-100	-136,402	-	-%

Are Funds Buying or Selling PHAT?

Are funds buying PHAT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PHAT

No. of Funds

Unveiling Phathom Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 10, 2024	takeda pharmaceutical co ltd	4.8%	2,790,480	SC 13D/A
Apr 01, 2024	takeda pharmaceutical co ltd	5.4%	3,153,217	SC 13D/A
Feb 12, 2024	carlyle group inc.	6.1%	3,496,808	SC 13G/A
Feb 09, 2024	invesco ltd.	5.5%	3,167,653	SC 13G/A
Jan 26, 2024	medicxi growth i lp	6.4%	3,673,602	SC 13G/A
Jan 25, 2024	takeda pharmaceutical co ltd	6.6%	3,755,583	SC 13D/A
May 26, 2023	frazier life sciences public fund, l.p.	10.7%	5,827,415	SC 13D/A
May 05, 2023	frazier life sciences public fund, l.p.	13.4%	5,827,415	SC 13D/A
Mar 09, 2023	carlyle group inc.	6.7%	2,935,106	SC 13G
Feb 14, 2023	avidity partners management lp	4.6%	1,900,000	SC 13G/A

Recent SEC filings of Phathom Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	8-K	Current Report
May 09, 2024	10-Q	Quarterly Report
Apr 12, 2024	DEFA14A	DEFA14A
Apr 12, 2024	DEF 14A	DEF 14A
Apr 12, 2024	ARS	ARS
Apr 10, 2024	SC 13D/A	13D - Major Acquisition
Apr 10, 2024	4	Insider Trading
Apr 01, 2024	SC 13D/A	13D - Major Acquisition
Mar 26, 2024	4	Insider Trading
Mar 07, 2024	8-K	Current Report

Peers (Alternatives to Phathom Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.2B	6.8B	19.54%	-2.80%	-8.07	7.03	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.0B	2.0B	0.98%	-26.98%	-57.12	9.47	75.20%	68.82%
BMRN	15.3B	2.5B	-12.72%	-14.31%	74.39	6.18	13.74%	186.89%
INCY	12.9B	3.8B	6.98%	-11.75%	17.35	3.43	8.58%	129.81%
MID-CAP
BBIO	5.3B	107.9M	6.22%	110.41%	-9.76	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-16.95%	-51.10%	-12.51	9.96	394.93%	39.61%
AXSM	3.6B	251.0M	9.36%	-4.29%	-12.12	14.31	73.58%	-86.73%
ARWR	2.7B	240.7M	-10.69%	-43.90%	-5.82	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.5K	3.08	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.44	4.66	60.38%	-34.49%
NVAX	1.8B	996.6M	206.31%	55.15%	-4.62	1.85	-26.66%	65.49%
CRBP	458.7M	881.7K	5.07%	336.18%	-13.59	481.06	-77.61%	33.36%
INO	294.6M	4.9M	3.08%	29.79%	-2.36	60.54	-54.97%	48.23%
IBIO	15.6M	2.1M	-10.40%	79.21%	-0.67	7.61	-13.45%	69.54%

Phathom Pharmaceuticals Inc News

Latest updates

Phathom Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)			(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q1
Revenue	-	1,912	-	-
Cost Of Revenue	-	426	-	-
Gross Profit	-	1,486	-	-
Operating Expenses	1.5%	71,440	70,390	30,077
S&GA Expenses	8.8%	62,010	56,997	18,598
R&D Expenses	-29.6%	9,430	13,394	11,479
Interest Expenses	31.8%	17,168	13,029	9,217
Net Income	-4.1%	-82,852	-79,570	-37,814
Net Income Margin	-22.3%	-361.63*	-295.59*	-
Free Cashflow	-56.0%	-69,060	-44,272	-39,883

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																				(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4
Assets	-13.9%	356	414	237	265	144	165	202	214	149	189	228	215	246	295	231	252	264	257	80.00	-
Current Assets	-14.4%	340	397	227	258	140	161	198	209	146	187	225	211	243	291	227	249	262	256	78.00	1.00
Cash Equivalents	-15.5%	322	381	214	249	130	155	197	207	138	183	225	210	238	287	226	247	257	244	74.00	1.00
Inventory	20.7%	1.00	1.00	0.00	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net PPE	-8.6%	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	-
Liabilities	3.8%	505	487	255	247	234	240	228	221	111	117	125	82.00	82.00	101	75.00	64.00	55.00	29.00	232	-
Current Liabilities	12.1%	43.00	39.00	24.00	22.00	14.00	26.00	23.00	21.00	11.00	19.00	28.00	40.00	41.00	56.00	28.00	13.00	5.00	4.00	207	2.00
Long Term Debt	8.1%	149	138	99.00	98.00	97.00	95.00	94.00	92.00	91.00	90.00	88.00	37.00	36.00	40.00	41.00	45.00	46.00	23.00	23.00	-
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	10.00	12.00	7.00	6.00	1.00	-	-	-	-
LT Debt, Non Current	-100.0%	-	138	99.00	98.00	97.00	95.00	94.00	92.00	91.00	90.00	88.00	37.00	36.00	40.00	41.00	45.00	-	23.00	-	-
Shareholder's Equity	-104.1%	-148	-72.76	-	18.00	-90.19	-74.81	-	-	38.00	72.00	103	132	164	194	156	188	209	228	-	-
Retained Earnings	-8.9%	-1,011	-928	-849	-805	-764	-727	-672	-620	-570	-529	-493	-456	-420	-385	-331	-297	-276	-256	-158	-1.29
Additional Paid-In Capital	0.8%	863	856	831	823	675	652	646	614	608	602	597	589	585	580	488	486	485	484	6.00	0.00
Shares Outstanding	1.0%	59.00	58.00	57.00	57.00	44.00	41.00	38.00	38.00	38.00	31.00	37.00	37.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	526	-	-	-	198	-	-	-	684	-	-	-	552	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-57.6%	-69,020	-43,797	-31,914	-22,200	-39,669	-41,041	-35,016	-25,716	-44,757	-41,262	-29,066	-28,364	-49,765	-28,200	-20,727	-9,344	-11,417	-23,384	-7,108	-5,211	-807
Share Based Compensation	-77.1%	5,626	24,584	6,140	7,253	7,048	6,657	5,816	5,885	5,775	4,338	4,419	4,237	3,818	2,379	2,070	828	563	-	-	-	-
Cashflow From Investing	91.6%	-40.00	-475	-939	-6.00	-214	-412	-134	-428	-67.00	-100	-14.00	-45.00	-169	-124	-183	-57.00	-676	-	-	-	-
Cashflow From Financing	-95.3%	9,900	211,993	13.00	141,502	14,072	-	24,596	-	-	163	44,029	104	412	89,459	-	-	25,000	192,771	-1,299	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PHAT Income Statement

2023-12-31

Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Gross Profit [Abstract]
Product revenue, net	$ 682	$ 0
Cost of revenue	167	0
Gross Profit	515	0
Operating expenses:
Research and development (includes related party amounts of $760 and $2,123, respectively)	49,899	71,441
Selling, general and administrative (includes related party amounts of $55 and $0, respectively)	117,928	100,999
Total operating expenses	167,827	172,440
Loss from operations	(167,312)	(172,440)
Other income (expense):
Interest income	7,876	2,132
Interest expense	(41,968)	(27,305)
Other (expense), net	(188)	(110)
Total other expense	(34,280)	(25,283)
Net loss and comprehensive loss	$ (201,592)	$ (197,723)
Net loss per share, basic	$ (3.93)	$ (5.05)
Net loss per share, diluted	$ (3.93)	$ (5.05)
Weighted-average shares of common stock outstanding, basic	51,289,092	39,118,215
Weighted-average shares of common stock outstanding, diluted	51,289,092	39,118,215

PHAT Balance Sheet

2023-12-31

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 381,393	$ 155,385
Prepaid expenses and other current assets	13,194	5,127
Accounts receivable, net	1,637	0
Inventory	1,208	0
Total current assets	397,432	160,512
Property, plant and equipment, net	2,146	1,207
Operating lease right-of-use assets	1,475	2,287
Restricted cash	2,863	505
Inventory, noncurrent	8,234	0
Other long-term assets	1,692	299
Total assets	413,842	164,810
Current liabilities:
Accounts payable (including related party amounts of $25 and $35 respectively)	12,601	9,997
Accrued expenses (including related party amountsof $2,694 and $2,499 respectively)	17,197	14,678
Accrued interest	1,146	854
Operating lease liabilities, current	726	708
Current portion of revenue interest financing liability	7,111	0
Total current liabilities	38,781	26,237
Long-term debt, net of discount	137,842	95,264
Revenue interest financing liability	299,816	109,525
Operating lease liabilities	462	1,098
Other long-term liabilities	9,700	7,500
Total liabilities	486,601	239,624
Commitments and contingencies (Note 4)
Stockholders' deficit:
Preferred stock, $0.0001 par value; authorized shares - 40,000,000 at December 31, 2023 and December 2022; no shares issued and outstanding at December 31, 2023 and December 2022
Common stock, $0.0001 par value; authorized shares - 400,000,000 at December 31, 2023 and December 2022; issued shares - 57,970,044 and 41,723,308 at December 31, 2023 and December 2022, respectively; outstanding shares - 57,970,044 and 41,468,871 at December 31, 2023 and December 2022, respectively	5	3
Treasury stock - 19 shares at December 31, 2023 and December 2022 respectively	0	0
Additional paid-in capital	855,921	652,276
Accumulated deficit	(928,685)	(727,093)
Total stockholders' deficit	(72,759)	(74,814)
Total liabilities and stockholders' deficit	$ 413,842	$ 164,810

About Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

CEO	Ms. Terrie J. Curran
WEBSITE	phathompharma.com
INDUSTRY	Biotechnology
EMPLOYEES	112

Phathom Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Phathom Pharmaceuticals Inc? What does PHAT stand for in stocks?

PHAT is the stock ticker symbol of Phathom Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Phathom Pharmaceuticals Inc (PHAT)?

As of Mon May 13 2024, market cap of Phathom Pharmaceuticals Inc is 566.04 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PHAT stock?

You can check PHAT's fair value in chart for subscribers.

What is the fair value of PHAT stock?

You can check PHAT's fair value in chart for subscribers. The fair value of Phathom Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Phathom Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PHAT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Phathom Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether PHAT is over valued or under valued. Whether Phathom Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Phathom Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PHAT.

What is Phathom Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, PHAT's PE ratio (Price to Earnings) is -2.3 and Price to Sales (PS) ratio is 829.96. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PHAT PE ratio will change depending on the future growth rate expectations of investors.